is glp-1 covered by medicaid Which Weight Loss Meds Are Medicaid? The 2026 State-by-State Breakdown Does Medicaid Pay for GLP-1
Description
Choose lower-fat meals, especially during dose escalation periods, as fatty foods can worsen GLP-1-related digestive symptoms

Current FDA labels document these patterns in detail: Wegovy (semaglutide) lists nausea (44% vs 16% placebo), vomiting (25% vs 6%), diarrhea (30% vs 16%), constipation (24% vs 11%), abdominal distension and eructation, with severe GI events in 4.1% versus 0.9% placebo.[2] Zepbound (tirzepatide) lists nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, eructation, and gastroesophageal reflux disease among common adverse reactions, with severe GI disease as a Warnings and Precautions item.[3] Both labels include postmarketing reports of ileus, severe constipation including fecal impaction, and acute kidney injury related to dehydration from severe GI symptoms

This study received financial assistance from the Finnish National Agency for Education (EDUFI) (OPH-16472022)

UACR, urine albumin-to-creatinine ratio
The discovery and development of liraglutide and semaglutide